Revolution Medicines Inc

RVMD remains in a Stage 2 uptrend with no active structural patterns, but price is currently rejecting at the 9- and 20-day EMAs and pulling back into the rising 50-day SMA. We maintain a medium-term bullish bias and will stalk for a firm hold and eventual reclamation of the faster EMAs around the 50-day SMA. A decisive break and close below the 50-day SMA with follow-through selling would invalidate the medium-term bullish bias.

• ↑FDA approved RASONQUE for metastatic pancreatic cancer with analysts forecasting $11.5B peak sales.
• ↑Phase 1/2 trials showed 42% confirmed response rate and 16-month median overall survival.
• ↓Q2 2026 net loss of $644M vs $248M prior year highlights profitability risk.